Literature DB >> 34177230

Reduction of Opioid Use With Enhanced Recovery Program for Total Knee Arthroplasty.

Garen Collett1, Allison P Insley1, Secherre Michaelis1, Sheryl Shaji1, Bobbi Feierstein1, John R Martell1.   

Abstract

BACKGROUND: Adequate pain control after total knee arthroplasty (TKA) is critically important to achieve early mobilization, shorten the length of hospital stay, and reduce postoperative complications. At Veterans Affairs North Texas Health Care System (VANTHCS) in Dallas, we implemented a multidisciplinary enhanced recovery after surgery (ERAS) protocol to deal with increasing length of stay and postoperative pain. We hypothesize that this protocol will reduce the overall opioid burden and decrease inpatient hospital length of stay in our TKA population.
METHODS: A retrospective review of all TKAs performed by a single surgeon at VANTHCS from 2013 to 2018 was conducted. A postoperative ERAS protocol was implemented in 2016. We compared perioperative opioid use and LOS between cohorts before and after protocol implementation.
RESULTS: Inpatient length of stay between cohorts was reduced from 66.8 hours for the standard of care (SOC) period to 22.3 hours in the ERAS cohort. Inpatient opioid use measured by total oral morphine equivalent doses averaged 169.5 mg and 66.7 mg for SOC and ERAS cohorts, respectively (P = .0001). Intraoperative use of opioids decreased from 57.4 mg in the SOC cohort to 10.5 mg in the ERAS cohort (P = .0001). Postanesthesia care unit (PACU) opioid use decreased from 13.6 mg (SOC) to 1.3 mg (ERAS) (P = .0002). There was no significant difference in complications between cohorts (P = .09).
CONCLUSIONS: Initiating a multidisciplinary ERAS protocol for TKA at VANTHCS significantly reduced inpatient length of stay and perioperative opioid use with no deleterious effects on complication rates. The ERAS protocol has major medical and financial implications for our unique VA population and the VA health care system.
Copyright © 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA.

Entities:  

Year:  2021        PMID: 34177230      PMCID: PMC8221830          DOI: 10.12788/fp.0124

Source DB:  PubMed          Journal:  Fed Pract        ISSN: 1078-4497


  28 in total

Review 1.  Liposomal bupivacaine infiltration versus femoral nerve block for pain control in total knee arthroplasty: A systematic review and meta-analysis.

Authors:  Jianbing Ma; Weijie Zhang; Shuxin Yao
Journal:  Int J Surg       Date:  2016-10-11       Impact factor: 6.071

2.  Local Infiltration Analgesia With Liposomal Bupivacaine Improves Pain Scores and Reduces Opioid Use After Total Knee Arthroplasty: Results of a Randomized Controlled Trial.

Authors:  Michael A Mont; Walter B Beaver; Stanley H Dysart; John W Barrington; Daniel J Del Gaizo
Journal:  J Arthroplasty       Date:  2017-07-25       Impact factor: 4.757

3.  Liposomal Bupivacaine Versus Standard Periarticular Injection in Total Knee Arthroplasty With Regional Anesthesia: A Prospective Randomized Controlled Trial.

Authors:  Sara J Hyland; David G Deliberato; Robert A Fada; Michael J Romanelli; Christy L Collins; Ray C Wasielewski
Journal:  J Arthroplasty       Date:  2018-11-23       Impact factor: 4.757

4.  A synthesis of oral morphine equivalents (OME) for opioid utilisation studies.

Authors:  Suzanne Nielsen; Louisa Degenhardt; Bianca Hoban; Natasa Gisev
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-12-22       Impact factor: 2.890

5.  Risk for Prolonged Opioid Use Following Total Knee Arthroplasty in Veterans.

Authors:  Katherine Hadlandsmyth; Mark W Vander Weg; Kimberly D McCoy; Hilary J Mosher; Mary S Vaughan-Sarrazin; Brian C Lund
Journal:  J Arthroplasty       Date:  2017-08-24       Impact factor: 4.757

6.  Controlling pain after total hip and knee arthroplasty using a multimodal protocol with local periarticular injections: a prospective randomized study.

Authors:  Hari K Parvataneni; Vineet P Shah; Holly Howard; Naida Cole; Amar S Ranawat; Chitranjan S Ranawat
Journal:  J Arthroplasty       Date:  2007-07-26       Impact factor: 4.757

7.  Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council.

Authors:  Roger Chou; Debra B Gordon; Oscar A de Leon-Casasola; Jack M Rosenberg; Stephen Bickler; Tim Brennan; Todd Carter; Carla L Cassidy; Eva Hall Chittenden; Ernest Degenhardt; Scott Griffith; Renee Manworren; Bill McCarberg; Robert Montgomery; Jamie Murphy; Melissa F Perkal; Santhanam Suresh; Kathleen Sluka; Scott Strassels; Richard Thirlby; Eugene Viscusi; Gary A Walco; Lisa Warner; Steven J Weisman; Christopher L Wu
Journal:  J Pain       Date:  2016-02       Impact factor: 5.820

8.  Improving total knee arthroplasty perioperative pain management using a periarticular injection with bupivacaine liposomal suspension.

Authors:  Mark A Snyder; Christina M Scheuerman; Justin L Gregg; Christopher J Ruhnke; Kathryn Eten
Journal:  Arthroplast Today       Date:  2016-01-11

9.  The efficacy of local liposomal bupivacaine infiltration on pain and recovery after Total Joint Arthroplasty: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Baocheng Zhao; Xinlong Ma; Jinli Zhang; Jianxiong Ma; Qing Cao
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

10.  Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017.

Authors:  Lawrence Scholl; Puja Seth; Mbabazi Kariisa; Nana Wilson; Grant Baldwin
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-01-04       Impact factor: 17.586

View more
  1 in total

Review 1.  Key Components, Current Practice and Clinical Outcomes of ERAS Programs in Patients Undergoing Orthopedic Surgery: A Systematic Review.

Authors:  Francesca Salamanna; Deyanira Contartese; Silvia Brogini; Andrea Visani; Konstantinos Martikos; Cristiana Griffoni; Alessandro Ricci; Alessandro Gasbarrini; Milena Fini
Journal:  J Clin Med       Date:  2022-07-20       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.